CKX Stock Overview
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cryoport, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.50 |
| 52 Week High | US$21.60 |
| 52 Week Low | US$8.50 |
| Beta | 1.59 |
| 1 Month Change | -7.19% |
| 3 Month Change | 12.32% |
| 1 Year Change | -16.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -37.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| CKX | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.0% | 0.3% | -0.5% |
| 1Y | -16.7% | -15.0% | 2.5% |
Return vs Industry: CKX underperformed the German Life Sciences industry which returned -14.8% over the past year.
Return vs Market: CKX underperformed the German Market which returned 1.8% over the past year.
Price Volatility
| CKX volatility | |
|---|---|
| CKX Average Weekly Movement | 8.9% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CKX has not had significant price volatility in the past 3 months.
Volatility Over Time: CKX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,025 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services.
Cryoport, Inc. Fundamentals Summary
| CKX fundamental statistics | |
|---|---|
| Market cap | €770.42m |
| Earnings (TTM) | -€100.29m |
| Revenue (TTM) | €217.44m |
3.6x
P/S Ratio-7.8x
P/E RatioIs CKX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CKX income statement (TTM) | |
|---|---|
| Revenue | US$233.26m |
| Cost of Revenue | US$133.92m |
| Gross Profit | US$99.33m |
| Other Expenses | US$206.92m |
| Earnings | -US$107.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 42.59% |
| Net Profit Margin | -46.12% |
| Debt/Equity Ratio | 77.7% |
How did CKX perform over the long term?
See historical performance and comparison